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A B S T R A C T
Background
Interleukin 2 receptor antagonists (IL2Ra) are used as induction therapy for prophylaxis against acute rejection in kidney transplant
recipients. Use of IL2Ra has increased steadily, with 38%of new kidney transplant recipients in theUnited States, and 23% in Australasia
receiving IL2Ra in 2002.
Objectives
This study aims to systematically identify and summarise the effects of using an IL2Ra, as an addition to standard therapy, or as an
alternative to other antibody therapy.
Search strategy
The Cochrane Renal Group’s specialised register (June 2003), the Cochrane Controlled Trials Register (in The Cochrane Library issue
3, 2002), MEDLINE (1966-November 2002) and EMBASE (1980-November 2002). Reference lists and abstracts of conference pro-
ceedings and scientific meetings were hand-searched from 1998-2003. Trial groups, authors of included reports and drugmanufacturers
were contacted.
Selection criteria
Randomised controlled trials (RCTs) in all languages comparing IL2Ra to placebo, no treatment, other IL2Ra or other antibody
therapy.
Data collection and analysis
Data was extracted and quality assessed independently by two reviewers, with differences resolved by discussion. Dichotomous outcomes
are reported as relative risk (RR) with 95% confidence intervals (CI).
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Main results
One hundred and seventeen reports from 38 trials involving 4893 participants were included. Where IL2Ra were compared with
placebo (17 trials; 2786 patients), graft loss was not significantly different at one (RR 0.83, 95% CI 0.66 to 1.04) or three years
(RR 0.88, 95% CI 0.64 to 1.22). Acute rejection (AR) was significantly reduced at six months (RR 0.66, 95% CI 0.59 to 0.74) and
at one year (RR 0.67, 95% CI 0.60 to 0.75). At one year, cytomegalovirus (CMV) infection (RR 0.82, 95% CI 0.65 to 1.03) and
malignancy (RR 0.67, 95% CI 0.33 to 1.36) were not significantly different. Where IL2Ra were compared with other antibody therapy
no significant differences in treatment effects were demonstrated, but adverse effects strongly favoured IL2Ra.
Authors’ conclusions
Given a 40% risk of rejection, seven patients would need treatment with IL2Ra to prevent one patient having rejection, with no definite
improvement in graft or patient survival. There is no apparent difference between basiliximab and daclizumab. IL2Ra are as effective
as other antibody therapies and with significantly fewer side effects
P L A I N L A N G U A G E S U M M A R Y
Interleukin 2 receptor antagonists (IL2Ra) reduce the risk of acute rejection episodes at six and twelve months after kidney
transplantation
Acute rejection is a major problem in the early period following kidney transplantation. Immunosuppressive drugs are used to prevent
this. IL2Ra, a new class antibody therapy, can be added to a patient’s existing immunosuppression to further reduce the risk of rejection.
This review found that IL2Ra reduced the risk of acute rejection at six and 12 months after kidney transplantation but did not improve
kidney or patient survival. IL2Ra treatment had fewer side effects than other antibody therapy.
B A C K G R O U N D
Kidney transplantation is the treatment of choice for patients with
end-stage renal disease (ESRD). In the developed world there are
approximately 280 patients per million population (pmp) with
a functioning kidney transplant, a figure which has increased
throughout the 1990s. The transplant rate is around 30 pmp and
between 30-40% of transplanted organs come from living donors.
Graft survival beyond five years has remained unchanged since the
1970s, with an average annual decline of approximately 5%.Wait-
ing lists for transplantation continue to grow, demand exceeding
organ availability. Strategies to increase donor organ availability
and to prolong kidney allograft survival have become priorities
in kidney transplantation ( ANZDATA 2002; UKTSSA 2002;
UNOS 2002).
Transplant outcome is influenced by many factors. In the absence
of immunosuppression, transplanted organs undergo progressive
immune mediated injury (rejection). Standard immunosuppres-
sive therapy consists of initial induction and then maintenance
regimes to prevent rejection, with short courses of more intensive
immunosuppressive therapy to treat episodes of acute rejection.
Standard protocols in use typically involve three drug groups each
directed to a site in the T-cell activation and proliferation cascade
which is central to the rejection process: calcineurin inhibitors (e.g.
cyclosporin, tacrolimus), anti-proliferative agents (e.g. azathio-
prine, mycophenolate mofetil) and steroids (prednisolone) (Hong
2000).
Short-term graft survival is related to control of the acute rejec-
tion process. The risk of graft rejection is greatest in the imme-
diate post transplant period, and immunosuppression is therefore
initiated at high levels. This is either by using higher doses of
the agents used in maintenance therapy, or by adding an anti-T
cell antibody preparation, either a polyclonal anti-lymphocyte an-
tibody (e.g. anti-thymocyte globulin) or a monoclonal antibody
(e.g. muromonab-CD3).
The major cause of long-term graft loss is chronic allograft
nephropathy, an ill-defined process characterised clinically by pro-
gressive deterioration in graft function, proteinuria and hyper-
tension and pathologically by scarring on biopsy. Chronic allo-
graft nephropathy is a consequence of immunological andnon-im-
munological injury. Immunological factors include HLA match-
ing, episodes of acute rejection and suboptimal immunosuppres-
sion. Important non-immunological factors implicated are donor-
2Interleukin 2 receptor antagonists for kidney transplant recipients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
organ characteristics, delayed graft function, recipient-related fac-
tors, hypertension, hyperlipidaemia and the acute and chronic tox-
icity of calcineurin inhibitors (Suthanthiran 1994).
Over recent years alternative immunosuppressive agents have been
developed with the aim of influencing the risk factors for chronic
allograft nephropathy and so increasing kidney allograft survival.
These agents reflect the progress in the understanding of cellular
and molecular mechanisms that mediate allograft rejection, and
aim to increase the selectivity and specificity of immunosuppres-
sion whilst avoiding the complications of over immunosuppres-
sion (infection and malignancy). These new agents are directed
at alternative sites in the T cell activation cascade and include
sirolimus and the interleukin-2 receptor antagonists (IL2Ra) basil-
iximab and daclizumab (Denton 1999; Pascual 2002).
IL2Ra use has increased globally year on year, with 38% of new
kidney transplant recipients in the United States, and 23% in
Australasia receiving IL2Ra in 2002 (ANZDATA 2002; UNOS
2002).
IL2Ra are humanised or chimeric (murine/human) IgG mono-
clonal antibodies to the alpha subunit of the IL2 receptor present
only on activated T lymphocytes. The binding of IL2 to its re-
ceptor induces second messenger signals to stimulate the T cell to
enter the cell cycle and proliferate, resulting in clonal expansion
and differentiation. IL2Ra inhibit this IL2 mediated activation.
The rationale for use of IL2Ra has been as induction agents in
combinationwith standard agents to try to prevent acute rejection,
or to minimise exposure to the calcineurin inhibitors (particularly
in recipients deemed at high risk of delayed initial graft function)
thereby ameliorating their short and long-term nephrotoxic side
effects (so called calcineurin inhibitor sparing regimes) (Goebel
2000; Cibrik 2001)
To date no combination of immunosuppressive agents has been
shown to prevent chronic allograft nephropathy or to prolong al-
lograft or patient survival. Current opinion favours minimising
early graft injury and using induction therapy (including IL2Ra)
to prevent acute rejection, particularly in high-risk patients. High-
risk groups include young adults and children, recipients of kid-
ney with pancreas transplant, and ’sensitised’ patients. Sensitised
patients are those with high titres of preformed circulating anti-
HLA antibodies, which may come about as a result of underly-
ing illness, previous transplantation, previous pregnancy or blood
transfusion. However there is no direct proof that a decrease in
early rejection rates translates into a uniform increase in long-term
graft survival for all (Pascual 2001; Vanrenterghem 2001).
There has, however, been considerable variability in the use of
standard immunosuppressive agents and the newer agents by clin-
icians, in combination and dosage regimen, both geographically
and within patient groups. It remains unclear whether new reg-
imens are more specific or simply more potent immunosuppres-
sants. There is concern that newer drugs or combinations, whilst
apparently improving early graft outcome, may in fact increase
the risk of malignant or cardiovascular disease in the longer term,
thereby curtailing patient survival (death with functioning allo-
graft). In the absence of clear evidence optimal maintenance ther-
apy continues to be debated, particularly the discontinuation of
both calcineurin inhibitors and corticosteroids after the first year
post transplantation (Vanrenterghem 2001).
The aim of this systematic review is to assess the contribution of
IL2Ra in terms of short and long-term benefits and harms, in
kidney transplant recipients.
O B J E C T I V E S
To evaluate the benefits and harms over and above standard im-
munosuppression of IL2Ra in kidney transplant recipients, when
they are added to a standard dual or triple therapy regimen, or
used in place of another agent. To determine whether the benefits
and harms vary in absolute or relative terms is dependant on the
type of IL2Ra used.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCT) and quasi-RCTs in which
IL2Ra are used to treat kidney transplant recipients.
Types of participants
Adults and children with ESRD that are the recipient of a first or
subsequent cadaveric or living donor kidney transplant. Recipients
who have received another solid organ in addition to a kidney
transplant (e.g. kidney and pancreas) were excluded.
Types of interventions
• IL2Ra given in the intra-operative period or at any time
post-transplantation, in combination with any other
immunosuppressive agents for any rationale (e.g. induction
therapy, prophylaxis against rejection, calcineurin sparing etc).
All dosage regimens were included.
• Control patients receive no IL2Ra, a different IL2Ra,
placebo or another agent.
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Types of outcome measures
The outcome measures relate to those used by transplant registries
to assess patient and graft survival. Outcome events were assessed
at one, three and six months, one, three and five years post-trans-
plantation.
Primary outcomes
• Patient mortality
• Graft loss (graft loss being dependence on dialysis,
excluding death with functioning allograft )
• Incidence of acute rejection (clinically suspected and
treated, or biopsy proven, or steroid resistant)
Secondary outcomes
• Graft loss or death with a functioning allograft
• Incidence of chronic allograft nephropathy (biopsy proven
or as specified by the authors)
• Incidence of viral, bacterial and fungal infectious
complications (including specifically cytomegalovirus (CMV) )
Diagnosis by culture, serology, antigen or antibody testing, or as
specified by authors.
• Incidence of treatment related adverse reactions; grouped
by system affected.
• Incidence of malignancy (non-melanocytic skin cancer and
other malignancy; either primary, donor related or recurrent)
Search methods for identification of studies
Relevant trials were obtained from the following sources (see Ad-
ditional Table 1)
1. Cochrane Renal Group specialised register of randomised
controlled trials (June 2003)
2. Cochrane Central Register of Controlled Trials
(CENTRAL - issue 3, 2003 in The Cochrane Library) for any
“New” records not yet incorporated in the specialised register
3. MEDLINE and Pre MEDLINE (1966 to November 2002)
were searched using the above terms, combined with the
optimally sensitive strategy for the identification of RCTs
(Dickersin 1994) (see Cochrane Renal Group Module).
4. EMBASE (1980 to November 2003) was searched using
terms similar to those used for MEDLINE and combined with a
search strategy for the identification of RCTs (Lefebvre 1996).
5. Reference lists of nephrology textbooks, review articles and
relevant trials.
6. Conference proceeding’s abstracts from nephrology
scientific meetings.
7. Letters seeking information about unpublished or
incomplete trials to investigators known to be involved in
previous trials.
Where duplicate publication was suspected authors were con-
tacted for clarification and if duplication was confirmed, the initial
full publication together with any subsequent publication which
added additional information (e.g. longer term follow-up data)
was included in the review.
Data collection and analysis
The review was undertaken by five reviewers (AW, EGP, GH, JRC,
JC). The search strategy described above was performed to identify
eligible studies (GH). The titles and abstracts were independently
screened by two reviewers (AW and EGH). Where necessary, the
full text was independently assessed by two reviewers. Disagree-
ment about inclusion was resolved by discussion with JRC and
JC.
Data extraction was performed independently by two reviewers
(AW and EGP) using a standardised form. Authors of published
work were contacted for clarification of unclear data. Data was
entered into RevMan twice (AW).
Quality of studies was assessed independently by two reviewers
(AW and GH)without blinding to journal or authorship using the
checklist developed for the Cochrane Renal Group Renal Group
2003. Discrepancies were resolved by discussion with JRC and JC.
The quality items assessed were allocation concealment, blinding
of investigators, subjects and outcomes assessment, intention-to -
treat analysis and completeness of follow-up.
Each item was assessed separately (shown below) rather than com-
bined in a scoring system.
Quality checklist
Allocation Concealment
• Adequate - Randomisation method described that did not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study
• Unclear - Randomisation stated but no information on
method used was available
• Inadequate - Method of randomisation used such as
alternate medical record numbers or unsealed envelopes.; Any
information in the study that indicated that investigators or
participants could influence intervention group
Blinding
• Blinding of investigators: Yes/No/Not stated
• Blinding of participants: Yes/No/Not stated
• Blinding of outcome assessor: Yes/No/Not stated
• Blinding of data analysis: Yes/No/Not stated
In trials where no placebo was used, or where the drugs in the
intervention and comparison arms had different dosing schedules
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then, unless otherwise clarified, both the investigators and the
participants were considered non-blinded.
Intention-to-treat analysis (ITT)
• Yes: Specifically reported by authors that ITT was
undertaken and this was confirmed on study assessment, or not
stated but evident from study assessment that ITT was
undertaken
• Unclear. Reported but unable to confirm on study
assessment, or not reported and unable to confirm by study
assessment.
• No: Lack of ITT confirmed on study assessment (Patients
who were randomised were not included in the analysis because
they did not receive the study intervention, they withdrew from
the study or were not included because of protocol violation)
regardless of whether ITT reported or not.
Participants who were randomised but subsequently did not re-
ceive a kidney transplant were considered to be justifiable exclu-
sions from the ITT population.
Completeness of follow-up
Percentage of participants for whom data was complete at defined
study end-point
Where interim analyses were reported ’not stated’ will be recorded
Statistical assessment
For dichotomous outcomes (e.g. malignancy or no malignancy)
results are expressed as risk ratio (RR) with 95% confidence in-
tervals (CI). Data was pooled using the random effects model but
the fixed effects model was also analysed to ensure robustness of
the chosen model and susceptibility to outliers. Heterogeneity was
analysed using a Chi squared test on N-1 degrees of freedom, with
a P of 0.05 for statistical significance and additionally I² was ex-
amined.
Subgroup analysis was used to explore possible sources of hetero-
geneity.
An attempt was made to examine for publication bias using a
funnel plot (Egger 1997).
R E S U L T S
Description of studies
See: Characteristics of included studies.
A total of 117 reports (publications and abstracts) of 38 trials qual-
ified for inclusion in the review (Additional Figure 1). The 38 com-
bined trials represented a total of 4938 randomised participants.
Seventeen of these trials (Shidban 2000; Ahsan 2002; Baczkowska
2002; Brennan 2002; deBoccardo 2002;Garcia2002;Khan2000;
Kumar 2002; Kyllonen 2002; Mourad 2002; Philosophe 2002;
van Riemsdijk 2002; ATLAS 2003; Pourfarziani 2003; Sandrini
2002; Shidban 2003; Tullius 2003) were available in abstract form
only (2037 participants), whilst the remaining 21(2901 partici-
pants) were published in 10 different journals. All trials identified
were in English.
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Figure 1. Identification of trials for inclusion
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Seventeen trials (2786 participants) (Kirkman 1989; Kirkman
1991; vanGelder 1995;Daclizumab triple 98;Daclizumab double
99; Kahan 1999; Nashan 1997; Davies/Lawen 2000; Folkmane
2001; Pisani 2001; Ponticelli 2001; Ahsan 2002; Baczkowska
2002; deBoccardo 2002; Kyllonen2002; Sandrini 2002; Sheashaa
2003) compared an IL2Ra with placebo or no treatment and
15 trials (1212 participants) (Soulillou/Cant 1990; Kriaa 1993;
Hourmant 1994; Flechner 2000; Shidban 2000; Lacha 2001;
Sollinger 2001; Brennan 2002; Kyllonen 2002; Lebranchu 2002;
Mourad 2002; Philosophe 2002; Pourfarziani 2003; Shidban
2003; Tullius 2003) compared IL2Ra to another mono- or poly-
clonal antibody (either monomurab-CD3, ATG or ALG). Two
trials (89 participants) (Khan 2000; Nair 2001) compared basilix-
imab with daclizumab, and the remaining five trials (Matl 2001;
Garcia 2002; Kumar 2002; van Riemsdijk 2002; ATLAS 2003)
involved IL2Ra in a unique comparison (different dosing of the
same IL2Ra, IL2Ra within a calcineurin inhibitor free regimen
and IL2Ra within a steroid reduced or steroid free regimen). Basil-
iximab was used in 59% of trials, daclizumab in 30%, and other
IL2Ra were used in 22% (either Anti-tac, BT563, 33B3.1 or Lo-
tac-1).
Information on the study population demographics was not avail-
able for all trials. The majority of trials were restricted to unsensi-
tised participants with low baseline risk for transplantation. How-
ever, 11 trials included participants with panel reactive antibodies
(PRA) of greater than 50% (Kirkman 1989; Soulillou/Cant 1990;
Kirkman 1991; Hourmant 1994; van Gelder 1995; Daclizumab
triple 98; Daclizumab double 99; Lacha 2001; Brennan 2002;
Pourfarziani 2003; Tullius 2003) although the proportion of these
high risk participants within these trials varied from 4-100%.
Eight trials (Hourmant 1994; Davies/Lawen 2000; Flechner
2000; Pisani 2001; Ponticelli 2001; Lacha 2001; Mourad 2002;
Philosophe 2002) included a proportion of participants who had
previously had a failed kidney transplant.
Baseline immunosuppression varied both within trials (where
three arms were investigated) and amongst trials. Cyclosporin was
used in 32 trials. In 16 trials cyclosporin was stated to be the mi-
croemulsion (Neoral) formulation (Nashan 1997; Kahan 1999;
Davies/Lawen 2000; Shidban 2000; Matl 2001; Pisani 2001;
Ponticelli 2001; Sollinger 2001; deBoccardo 2002; Brennan 2002;
Kyllonen 2002; Lebranchu 2002; Mourad 2002; Sandrini 2002;
Shidban 2003; Sheashaa 2003), in 13 trials the formulation was
not stated, and the remainder used the earlier solution formulation
(Sandimmun) (Kirkman 1989; Kirkman 1991). Tacrolimus was
used in seven trials (Khan 2000; Ahsan 2002; Philosophe 2002;
Garcia 2002; van Riemsdijk 2002; ATLAS 2003; Tullius 2003).
The reporting of outcome measures was variable. Only three trials
reported incidence of chronic allograft nephropathy (Kriaa 1993;
Kumar 2002; Sheashaa 2003). Reporting of harms was limited
and inconsistent. Participants with any infection were reported in
52% of trials, however a further 21% trials also assessed infection,
but expressed their results as ’infectious episodes’, and so this data
could not be combined. Reporting of adverse reactions directly
relating to drug administration was found only in trials where an
IL2Ra was compared to another antibody preparation.
Risk of bias in included studies
Reporting of details of trial methodology was incomplete for the
majority of trials (Additional Table 2; Table 3; Table 4).
Allocation concealment
Five trials (Kirkman 1989; Soulillou/Cant 1990; Kirkman 1991;
Nashan 1997; Ponticelli 2001) (14%) reported adequate alloca-
tion concealment. Of the remaining 33 trials, 32 (84%) were ran-
domised but gave no information on the method used, and one
trial (Nair 2001)(3%) used inadequate methods.
Blinding
Nine trials (van Gelder 1995; Nashan 1997; Daclizumab triple
98; Daclizumab double 99; Kahan 1999; Davies/Lawen 2000;
Ponticelli 2001; deBoccardo 2002; Sandrini 2002) reported blind-
ing of both participants and investigators. There were no trials
that reported blinding status of either outcome assessors or data
analysts.
Intention-to-treat analysis
ITT analysis was confirmed in 10 trials (Hourmant 1994; Nashan
1997; Daclizumab triple 98; Daclizumab double 99; Kahan
1999; Matl 2001; Ponticelli 2001; Ahsan 2002; Lebranchu 2002;
Sheashaa 2003) (26%), unclear in a further 24 trials (68%) and
not undertaken in the remaining four trials (van Gelder 1995;
Soulillou/Cant 1990; Sollinger 2001; ATLAS 2003) (8%).
Completeness of follow-up
Completeness of follow-up was clear in 14 trials (Kirkman 1989;
Kirkman 1991; Nashan 1997; Daclizumab triple 98; Daclizumab
double 99; Kahan 1999; Khan 2000; Folkmane 2001; Ponticelli
2001; Sollinger 2001; Ahsan 2002; Lebranchu 2002; ATLAS
2003) (38%) with values that ranged from 89-100%, but was
neither reported nor deducible in the remaining 24 trials (62%).
Effects of interventions
IL2Ra compared with placebo/no treatment
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Results were homogeneous across all outcomes, with no differ-
ences demonstrated between the different IL2Ra used and the dif-
fering combinations of additional immunosuppressants. Graft loss
favoured the use of IL2Ra, but was not significantly different at
one year (Outcome 01.02-03: RR 0.83, 95% CI 0.66 to 1.04)
or three years (Outcome 01.02-04: RR 0.88, 95% CI 0.64 to
1.22). Incidence of clinically diagnosed acute rejection within six
months of transplantation was reduced by 34% for those treated
with an IL2Ra (Outcome 01.04-04: RR 0.66, 95% CI 0.59 to
0.74) and at one year (Outcome 01.04-05: RR 0.67, 95%CI 0.60
to 0.75). This advantage was similar for biopsy proven rejection,
showing a 36% reduction. Treatment with an IL2Ra showed a
substantial effect in preventing steroid resistant rejection, reducing
incidence at six months by 49% (Outcome 01.05-02: RR 0.51,
95% CI 0.38 to 0.67). CMV infection was reduced in IL2Ra
treated patients, but the difference was not statistically significant
at one year(Outcome 01.07-03: RR 0.82, 95% CI 0.65 to 1.03).
All other outcomes favoured the use of IL2Ra, but none reached
statistical significance.
IL2Ra compared with other mono or polyclonal
antibody preparations
IL2Ra were equally as effective as other mono and polyclonal an-
tibodies in preventing acute rejection. No statistically significant
differences in treatment effect were demonstrated for graft loss,
mortality, CMV infection or malignancy. Adverse reactions to the
study drug were not widely reported, but statistically significant
differences were shown for fever (Outcome 02.22: RR 0.41, 95%
CI 0.17 to 1.00), leucopaenia (Outcome 02.20: RR 0.21, 95%
CI 0.10 to 0.46), thrombocytopaenia (Outcome 02.21: RR 0.26,
95% CI 0.16 to 0.41) and overall adverse reactions (Outcome
02.17: RR 0.38, 95% CI 0.17 to 0.86), in favour of IL2Ra com-
pared with other antibody therapies.
Significant heterogeneity amongst trials was demonstrated for the
incidence ofCMV(sixmonths only:χ2 =12.65, df = 3; P =0.005),
and total adverse reactions (χ2 = 14.14, df = 3; P = 0.003). I2 for
CMV was 76.3% and for adverse reactions 78.8%. The largest
trial (Brennan 2002) contributing to both analyses was identified
as themain cause of the heterogeneous results. Sensitivity analysis,
by removal of this trial from each analysis, left three trials with
homogeneous results strongly favouring IL2Ra (CMV: RR 0.37,
95% CI 0.22 to 0.62, χ2 = 0.25 df = 2, P = 0.88; I2 = 0%;
adverse reactions: RR 0.29, 95% CI 0.18 to 0.47, χ2 = 1.77,
df = 2, P = 0.41, I2 = 0%). This was not explicable by either
baseline immunosuppression, CMV prophylaxis protocol, or by
trial quality.
The comparative efficacy of different IL2Ra
preparations
The two trials (Khan 2000; Nair 2001) comparing basiliximab
and daclizumab head to head were small (n = 82 total). Outcomes
were not reported at the same time point, and for the majority of
outcomes zero events occurred, so data could not be combined in
a meaningful way. Indirect comparison, by sub-grouping trials by
their intervention (daclizumab or basiliximab), showed no clear
difference for any outcomes. Adding basiliximab to a double or
triple therapy regimen had the same benefit as adding daclizumab
in preventing acute rejection at six months(basiliximab -Outcome
0.6.04-01: RR 0.67, 95% CI 0.59 to 0.77 versus daclizumab -
Outcome 0.6.04-04: RR 0.66, 95% CI 0.53 to 0.77).
Additional comparisons
The other five trials (Matl 2001; Garcia 2002; Kumar 2002; van
Riemsdijk 2002; ATLAS 2003) examined unique comparisons,
and so no summary beyond their individual results was possible.
D I S C U S S I O N
The use of an IL2Ra in addition to standard dual or triple therapy
significantly reduces acute rejection within the first year post trans-
plantation. This is a class effect, as there is no evidence that the
effects of basiliximab and daclizumab are different. Although use
of an IL2Ra in addition to standard therapy favours graft survival,
the effect was not significant. There is no demonstrable difference
in acute rejection rates or graft loss among IL2Ra and other mono
or polyclonal antibody preparations used in this context. Adverse
drug reactions affect significantlymore patients receiving antibody
preparations other than IL2Ra. CMV infection is relatively re-
duced when IL2Ra are used, whatever the comparative arm, but
the difference did not reach statistical significance. The short fol-
low-up duration of all trials was insufficient to clarify differences
in the incidence of new malignancies. It was not possible to draw
any conclusions about the effect of IL2Ra on chronic allograft
nephropathy as this outcome was largely ignored by triallists.
Strengths and limitations
This meta-analysis was undertaken with deliberately broad inclu-
sion criteria, to better explore the totality of evidence available.
The results demonstrated a remarkable consistency of effect for
IL2Ra. Despite this, there was still insufficient power to show def-
inite reduction in some important outcomes. Graft loss, including
death with a functioning allograft, suggested a 17% reduction at
one year for those treated with an IL2Ra in addition to standard
regimens. However, lack of power resulted in wide confidence in-
tervals around this estimate (0.66 to 1.04), with the result that,
although tantalisingly close, the reduction was not statistically sig-
nificant. Summary estimates of complications of immunosuppres-
sion, such as CMV infection and malignancy, were also under-
powered to show a difference in treatment effect, although the
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RR of all trials favoured IL2Ra, over placebo and over other an-
tibodies. In order to clarify these uncertainties, the importance of
publishing further follow-up data from the RCTs contributing to
this review is paramount.
The applicability of the meta-analysis results to other populations
and settingsmay be limited by the circumstances of the constituent
trials. The recipient population was not stated for 6 trials, and lim-
ited information was available for 12 trials. Seven trials (Kirkman
1989; Soulillou/Cant 1990; Nashan 1997; Daclizumab triple 98;
Daclizumab double 99; Lebranchu 2002; Shidban 2003) were
conducted in recipients of their first cadaveric graft, and where tri-
als included living donor grafts, these were a minority. Only three
small trials (Hourmant 1994; Pourfarziani 2003; Lacha 2001)
were conducted exclusively in ’high risk’ recipients, and the RCTs
containing mixed risk participants did not report stratified results.
However, the high level of homogeneity of results between RCTs
for the majority of outcomes, particularly the primary outcomes
of graft loss and acute rejection, suggests that the results are likely
to be generalisable to populations of greater and lesser risk.
Harms were reported in insufficient detail, or were measured or
grouped differently amongst trials, making it impossible to ade-
quately determine the relative frequency of adverse events, or to
summarise the drawbacks of therapy in an informative way. How-
ever, this is not a problem peculiar to this review, but is common
to many RCTs and systematic reviews (Cuervo 2003).
In an attempt to minimise publication bias, this meta-analysis in-
cluded both unpublished data and data from conference abstracts.
We also made strenuous efforts to include non-English language
sources. Fourteen (38%) trials included were not present on the
electronic databases, and 17 (46%) had not yet been reported
in journal format. Examination of forest plots for both Il2Ra vs
placebo and Il2Ra vs other antibody shows a symmetrical dis-
tribution around the point estimate of effect, suggesting there is
minimal publication bias (Figure 2; Figure 3; Figure 4). Confin-
ing a meta-analysis to published data or English language alone
has been previously demonstrated to over-estimate positive treat-
ment effects (Egger 1997). Examination of this approach led to
the inclusion of preliminary results from current on-going RCTs;
whether or not this may lead to bias in results has not been previ-
ously investigated, to our knowledge.
9Interleukin 2 receptor antagonists for kidney transplant recipients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Forest plot for Il2Ra vs other antibody; graft loss
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Figure 3. Forest plot for IL2Ra vs placebo/no treatment, outcome graft loss
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Figure 4. Forest plot for IL2Ra vs placebo/no treatment, outcome malignancy
The internal validity of the design, conduct and analysis of the
included RCTs was difficult to assess because of the omission of
important methodological details in the trial reports. Only two
trials adequately reported all four methodological quality items
assessed, despite 14 RCTs having been published in journals since
the advent of the CONSORT statement Begg 1996. The internal
validity of RCTs reported so far only in abstract form, was even
more difficult to ascertain (Moher 1999). Thus it is impossible
to exclude the possibility that elements of internal biases may be
present in the results of the meta-analysis.
Clinical implications
When added to standard dual or triple therapy, IL2Ra reduced
the risk of clinically diagnosed acute rejection by 34% and of
steroid resistant rejection by 49%, over standard therapy alone.
The combined risk of acute rejection in the placebo arm was 40%,
and of steroid resistant rejection 16%. Based upon these relative
risks, for every 100patients treatedwith IL2Raone could expect 14
fewer to experience acute rejection, and eight fewer to experience
steroid resistant rejection. The number needed-to-treat in order to
prevent one patient experiencing rejection is seven, and of steroid
resistant rejection 13. These results concur with a previous, more
limited meta-analysis of fewer RCTs which examined the addition
of IL2Ra to cyclosporin based therapy (Adu 2003).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
IL2Ra show significant benefit in reducing acute allograft rejec-
tion, but not graft loss, in kidney transplant recipients when added
to standard therapy. IL2Ra are as efficacious as other mono or
polyclonal antibody preparations, and with significantly fewer side
effects. Basiliximab and daclizumab are equally effective.
Implications for research
There was insufficient information in the reported data of the
RCTs in this review to undertake a formal economic evaluation,
based on the meta-analysis results, of the efficacy of IL2Ra. Any
excess costs arising from the addition of an IL2Ra to standard
regimens, or the substitution of an IL2Ra for a different antibody
preparation could not be calculated. This would be possible only
if more specific data were available, allowing the drug costs to be
offset against the costs of treating rejection and infection.
Despite the homogeneity of results across the populations of the
pooled trials, there was under representation of high risk partic-
ipants. Future trials involving patients at higher baseline risk of
acute rejection would confirm the benefits in this subgroup. A trial
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of IL2Ra compared to ATG may be particularly helpful. The im-
portance of follow-up prolonged beyond one year cannot be over
emphasised, particularly to clarify the risks and eventual outcome
of harms from differing immunosuppressive treatment strategies.
Many of the uncertainties of themeta-analysis might be clarified if
meta-analysis of individual patient data were possible. This would
increase the statistical power of the analysis, and thus might clarify
the estimates of effect which approach, but do not reach, statistical
significance. Individual data analysis would also allow time-to-
event data to be incorporated, and allow more flexible analysis
of patient subgroups and outcomes. However, if complete data
were not available from all RCTs, then analysis of only selected
data would obviously risk the introduction of bias to the estimates
(Clarke 2001).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahsan 2002
Methods Single centre (USA)
Participants N=100 (50/50)
70% cadaveric donors
100% 1st transplant
Interventions Daclizumab vs nothing
reduced dose daclizumab; 20mg/kg once
Baseline immunosuppression
Tacrolimus (0.16-0.2: 10-15)
MMF (1)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
delayed graft function
malignancy
Notes 1 year follow-up
significantly younger patients in control group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
ATLAS 2003
Methods Multicentre (Poland, Czech Republic, Finland, Sweden)
Participants N=457 (152/151/147)
donor and recipient status not stated
Interventions 1. Basiliximab with tacrolimus
2. Tacrolimus with MMF
3. Tacrolimus with MMF and steroids
Tacrolimus (0.2: 5-15)
MMF (2)
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ATLAS 2003 (Continued)
Outcomes mortality
graft loss
acute rejection
CMV
Notes 6 month follow-up.
On-going trial.
Data from abstract only.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Baczkowska 2002
Methods Single centre (Poland)
Participants N=32 (16/16)
donor and recipient status not stated
’low risk patients’
Interventions Daclizumab vs nothing
Baseline immunosuppression
Cyclosporin (5-10:ns) - lower dose in daclizumab group
MMF (2)
steroids
Outcomes acute rejection
Notes 3 month follow-up only.
Trial on-going.
Data from abstract only
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Brennan 2002
Methods Multicentre (28 from USA and Europe)
Participants N=260 (126 vs 134)
100% cadaveric
number of 1st transplants not stated
Interventions Basiliximab vs ATG (Thymoglobulin)
Baseline immunosuppression
Cyclosporin (12-16: ns)
MMF (2)
steroids
Outcomes acute rejection
infection/CMV
adverse reactions
malignancy
Notes 6 month follow up.
On going study.
Data from abstracts and additional data provided by author.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Daclizumab double 99
Methods Multicentre (19 from Europe, Australia,Canada)
Participants N=275 (141/134)
100% cadaveric donors
100% 1st transplants
Interventions Daclizumab vs placebo
Baseline immunosuppression
Cyclosporin (10: ns)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
delayed graft function
malignancy
23Interleukin 2 receptor antagonists for kidney transplant recipients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Daclizumab double 99 (Continued)
Notes Pooled analysis of Daclizumab double and triple therapy trials published after primary studies. Data used
only when presented separately for each trial.
3 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Daclizumab triple 98
Methods Multicentre ( 17 from USA,Canada, Sweden)
Participants N=260 (126 vs 134)
100% cadaveric donors
100% 1st transplants
Interventions Daclizumab vs placebo
Baseline immunosuppression
Cyclosporin (ns:ns)
Azathioprine (ns)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
delayed graft function
malignancy
Notes Pooled analysis of Daclizumab double and triple therapy trials published after primary studies. Data used
only when presented separately for each trial.
3 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Davies/Lawen 2000
Methods Multicentre (16 from Europe, USA, Canada)
Participants N=123 (59/64)
76% cadaveric donors
89% 1st transplants
Interventions Basiliximab vs placebo
Baseline immunosuppression
Cyclosporin (8-10: 100-400)
MMF (2-3)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
delayed graft function
malignancy
Notes 1 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
de Boccardo 2002
Methods Multicentre (31 from Argentina, Brazil, Costa Rica, Chile, Mexico)
Participants N=310 (ns/ns)
45% cadaveric donors
number 1st transplants not stated
Interventions Basiliximab vs placebo
Baseline immunosuppression
Cyclosporin (10:ns)
Azathioprine (1-2)
steroids
Outcomes mortality
graft loss
acute rejection
malignancy
Notes Number randomised in each group not stated, calculated from given proportions.
6 month follow-up.
Trial on-going.
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de Boccardo 2002 (Continued)
Data from abstract only
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Flechner 2000
Methods Single centre (USA)
Participants N = 45 (23/22)
91% cadaveric donors
1st and 2nd transplants - numbers not stated
Interventions Basiliximab vs muromonab-CD3
baseline immunosuppression
cyclosporin (ns:ns)
MMF (2)
steroids
Outcomes mortality
graft loss
acute rejection
Notes Follow-up range 1-12 months (median 6.4). Data contributes to 6 month outcome.
Trial on-going
Data from abstract.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Folkmane 2001
Methods 1 centre (Latvia)
Participants N=71 (23 vs 23 vs 25)
100% cadaveric donors
all 1st or 2nd Tx.
Interventions 1. Basiliximab, cyclosporin, azathioprine, steroids
2. Cyclosporin, MMF, steroids
3. Cyclosporin, Azathipoprine, steroids
cyclosporin (ns: 150-300)
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Folkmane 2001 (Continued)
azathioprine (1-2)
MMF (2)
Outcomes graft loss
acute rejection
CMV
Notes Group 2 and 3 combined for analysis in IL2Ra v no treatment comparison
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Garcia 2002
Methods Single centre (Brazil)
Participants N=49 (23/26)
0% cadaveric donors, 100% living donors
100% 1st transplants
’low risk’
Interventions 1. Daclizumab, MMF, steroids
2. Tacrolius, azathioprine, steroids
tacrolimus (0.1-0.15:ns)
azathioprine (2)
MMF (2)
Outcomes mortality
graft loss
acute rejection
infection
Notes Follow-up range 5-10 months (mean 7.8). Data contributes to 6 month outcome.
On-going trial.
Data from abstract only
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Hourmant 1994
Methods Single centre (France)
Participants N=40 (20/20) .
% cadaveric donors not stated
0% 1st transplants, 100% re-transplants
Interventions 33B3.1 vs ATG.
10mg/d vs 1mg/kg/d, both for 10 days from transplantation
baseline immunosuppression
cyclosporin (8:150-250)
azathioprine (2)
steroids
Outcomes mortality
graft loss
acute rejection
CMV
Notes 1 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Kahan 1999
Methods Multicentre ( 21 from USA)
Participants N=348 (174 vs 174)
70% cadaveric donors
100% 1st transplant
Interventions Basiliximab vs placebo
baseline immunosuppression
Cyclosporin (ns: 150-450)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
delayed graft function
malignancy
Notes 1 year follow-up
28Interleukin 2 receptor antagonists for kidney transplant recipients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kahan 1999 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Khan 2000
Methods Single centre (USA)
Participants N=59 (29/30)
donor source and recipient status not stated
Interventions Basiliximab vs daclizumab
with tacrolimus or cyclosporin (numbers not stated)
and MMF or azathioprine (numbers not stated)
Outcomes acute rejection
Notes 3 month follow-up
trial on-going.
data from abstract only
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Kirkman 1989
Methods 2 centres (USA)
Participants N=21 (12 vs 9).
100% cadaveric donors
100% 1st transplants
Interventions Anti-tac vs none.
20mg qid for 10 days from transplantation
baseline immunosuppression
cyclosporin
steroids
+/- azathioprine (numbers unstated)
Outcomes mortality
graft loss
acute rejection
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Kirkman 1989 (Continued)
Notes Study has 3 protocols; only data from protocol 1 included here. Additional data, from protocol 2 and 3,
recorded in Kirkman 1991.
Range of follow-up given, 12-21 months, contributes to 1 year outcome data
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Kirkman 1991
Methods 2 centres (USA)
Participants N=80 (40 vs 40)
100% cadaveric donors
100% 1st transplants
Interventions Anti-tac vs nothing
20mg qid for 10 days from transplantation
baseline immunosuppression
cyclosporine (4-8: ns) - lower dose in anti-tac group
azathioprine (2)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
delayed graft function
Notes Range of follow-up available overall, 6-26 months. Data contributes to time frame stated for each outcome
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Kriaa 1993
Methods Single centre (France)
Participants N=40 (20 vs 20)
100% cadaveric donors
% 1st transplants not stated
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Kriaa 1993 (Continued)
Interventions Lo-tact-1 vs ALG.
10mg/d for 10days, vs 15ml/d for 14days
Cyclosporin (8: ns)
Azathioprine (1)
steroids
Outcomes mortality
graft loss
acute rejection
chronic allograft nephropathy
infection/CMV
adverse reaction
Notes 1 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Kumar 2002
Methods Single centre (USA)
Participants N=27 (17 vs 10)
donor source and number previously transplanted not stated
all ’non sensitised’
Interventions 1. basiliximab (20mg day 0, 4, 60, 64) with steroids for 1 week
2. basiliximab (20mg day 0,4) with standard steroid
Cyclosporin (ns: ns)
MMF (ns)
Outcomes mortality
graft loss
acute rejection
chronic allograft nephropathy
Notes 1 year follow-up
data from abstract only
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Kyllonen 2002
Methods Single centre (Finland)
Participants N=155 (52/52/51)
100% cadaveric donors
% 1st transplants not stated
Interventions 1. Basiliximab with initial low dose cyclosporin (5 mg/kg/d) and antiproliferative
2. ATG bolus with initial low dose cyclosporin (5 mg/kg/d) and antiproliferative
3. conventional cyclosporin dose (ns) with antiproliferative
MMF/azathioprine (ns)
steroids
Outcomes mortality
graft loss
acute rejection
delayed graft function
Notes Number randomised in each group not stated, calculated from given proportions.
Group 1 and 3 analysed in IL2Ra vs placebo/no treatment comparison
Group 1 and 2 analysed in IL2Ra vs other antibody comparison
1 year follow-up.
data from abstract only
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Lacha 2001
Methods Single centre (Czech Republic)
Participants N=28 (14 vs 14).
all ’high risk’.
58% 1st transplants
donor source not stated
Interventions Daclizumab vs muromonab-CD3
2mg/kg then 1mg/kg on day 7,14 and 28. vs 5mg day 1 then 2.5mg day 2-7.
Cyclosporine (8: ns)
MMF (2)
steroids
Outcomes graft loss
acute rejection
CMV
adverse reaction
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Lacha 2001 (Continued)
Notes 6 month follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Lebranchu 2002
Methods Multicentre (9, France)
Participants N=103 (52/51)
100% 1st transplants
100% cadaveric donors
Interventions Basiliximab vs ATG (thymoglobulin)
baseline immunosuppression
Cyclosporin (6-8: 150-200)
MMF (2)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
delayed graft function
adverse reaction
malignancy
Notes 1 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Matl 2001
Methods Multicentre (Czech Republic, Poland,
Participants N=202
100% 1st transplants
100% cadaveric donors
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Matl 2001 (Continued)
Interventions Standard basiliximab 20mg x 2 vs single dose 20mg basiliximab
Cyclosporin (10: ns)
azathioprine (1-2)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
malignancy
Notes 1 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Mourad 2002
Methods Multicentre (France)
Participants N=89 (46 vs 43)
98.5% cadaveric donors
89.5 % 1st transplants
Interventions Basiliximab vs ATG (thymoglobulin)
baseline immunosuppression
Cyclosporin (6: ns)
MMF (2)
steroids
Outcomes mortality
graft loss
acute rejection
CMV
delayed graft function
adverse reaction
Notes on-going trial
month follow-up.
data from abstracts only.
Risk of bias
Item Authors’ judgement Description
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Mourad 2002 (Continued)
Allocation concealment? Unclear B - Unclear
Nair 2001
Methods Single centre (Kuwait)
Participants N=23 (10 vs 13)
26% cadaveric donor
100% 1st transplant
Interventions Basiliximab vs daclizumab
Cyclosporin (7: ns)
MMF (2)
steroids
Outcomes mortality
graft loss
acute rejection
infection
Notes quasi randomised - alternate patients
Follow-up range 9-12 (median 10) months. Data contributes to 1 year outcomes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Nashan 1997
Methods Multicentre (21 from Germany, UK, France, Canada)
Participants N=380 (193 vs 187)
100% cadaveric donors
100% 1st transplant
Interventions Basiliximab vs placebo
baseline immunosuppression
Cyclosporin (ns: 150-450)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
malignancy
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Nashan 1997 (Continued)
Notes 1 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Philosophe 2002
Methods Single centre (USA)
Participants N=50 (26/24)
all ’high risk for delayed graft function’.
92% 1st transplant
donor source not stated
Interventions Daclizumab vs muromonab-CD3
daclizumab 1mg/kg day 0 and day 5
baseline immunosuppression
Tacrolimus (ns: ns)
MMF (ns)
steroids
Outcomes mortality
graft loss
acute rejection
Notes 1 year follow-up.
on-going trial
data from abstracts.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Pisani 2001
Methods Single centre (Italy)
Participants N=32 (10 vs 9 vs 13)
donor source unstated
81% 1st transplant
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Pisani 2001 (Continued)
Interventions Group 1 and 2 basiliximab vs group 3 placebo
baseline immunosuppression
cyclosporin (8: 350-400)
MMF (1.5)
steroids
(steroids withdrawal at 6 months in gp B)
Outcomes mortality
graft loss
acute rejection
infection/CMV
delayed graft function
Notes Study designed to investigate steroid withdrawal from 6 months.
Trial on-going
Follow-up range 6-12 months; outcome data contributes to 6 month time point
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Ponticelli 2001
Methods Multicentre (31 from Europe, Israel, Mexico, South Africa)
Participants N=340 (168 vs 172)
83% cadaveric donors
93% 1st transplants
Interventions Basiliximab vs placebo
baseline immunosuppression
cyclosporin (10: 150-300)
azathioprine (1-2)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
delayed graft function
malignancy
Notes 1 year follow-up
Risk of bias
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Ponticelli 2001 (Continued)
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Pourfarziani 2003
Methods Single centre (Iran)
Participants N= 25
all ’immunologically high risk’
0% 1st transplants, 100% re-transplants
0% cadaveric donors, 100% living donors
Interventions Daclizumab vs ALG
Cyclosporin (ns: ns)
MMF (ns)
steroids
Outcomes graft loss
acute rejection
adverse reaction
Notes Trial on-going.
1 year follow-up.
Data from abstract only.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Sandrini 2002
Methods Multicentre (Italy)
Participants N=156 (79 vs 77)
100% 1st transplant
donor source not stated
Interventions Basiliximab vs placebo
cyclosporin (ns: ns)
Azathioprine (ns)
steroids
Outcomes mortality
graft loss
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Sandrini 2002 (Continued)
acute rejection
malignancy
Notes 1 year follow-up
Trial on going. data from abstracts only
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Sheashaa 2003
Methods Single centre (Egypt)
Participants N=100
0% cadaveric donors, 100% living donors
100% 1st transplants
Interventions Basiliximab vs nothing
baseline immunosuppression
cyclosporin (8: 125-150)
azathioprine (1)
steroids
Outcomes mortality
graft loss
acute rejection
chronic allograft nephropathy
infection/CMV
malignancy
Notes 3 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Shidban 2000
Methods SIngle centre (USA)
Participants N=48 (22 vs 20)
1st transplants ns
100% cadaveric donors
Interventions Basiliximab vs muromonab-CD3
baseline immunosuppression
Cyclosporin (ns:ns)
MMF (ns)
steroids
Outcomes mortality
graft loss
acute rejection
Notes 6 months follow-up.
Additional historical controls reported, but excluded from analyses of outcomes here.
data from abstract only
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Shidban 2003
Methods Single centre (USA)
Participants N=75 (25 vs 50)
100% cadaveric donors
100% 1st transplants
Interventions Basiliximab vs ATG (thymoglobulin)
baseline immunosuppression
Cyclosporin (ns: ns)
MMF (ns)
steroids
Outcomes acute rejection
delayed graft function
Notes 6 month follow-up.
trial on-going
data from abstract only
Risk of bias
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Shidban 2003 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Sollinger 2001
Methods Multicentre (6, USA)
Participants N=138 (70 vs 68)
62% cadaveric donors
81% 1st transplants
M/F 37/33 vs 42/23
Interventions Basiliximab vs ATG (ATGAM)
baseline immunosuppression
Cyclosporin (6-10: ns)
MMF(2-3)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
delayed graft function
adverse reaction
malignancy
Notes 1 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Soulillou/Cant 1990
Methods Multicentre (3, France)
Participants N=100 (50 vs 50)
100% cadaveric donors
100% 1st transplant
Interventions 33B3.1 vs ATG (thymoglobulin)
10mg daily for 10 days vs 2mg/kg for 14 days
baseline immunosuppression
cyclosporin (8: 300-600) - introduced day 14 both groups
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Soulillou/Cant 1990 (Continued)
azathioprine (2)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
delayed graft function
adverse reaction
Notes 1 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Tullius 2003
Methods Multicentre (Germany)
Participants N=124 (62 vs 62)
100% cadaveric donors
75% 1st transplants
Interventions Basiliximab vs ATG
tacrolimus (0.2: ns)
steroids
Outcomes mortality
graft loss
acute rejection
CMV
Notes Basiliximab group significantly greater proportion with PRA>50%
data from abstract only
1 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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van Gelder 1995
Methods Single centre (Netherlands)
Participants N=60 (30 vs 30)
78% cadaveric donors
100% 1st transplant
Interventions BT563 vs placebo.
10mg/d for 10 days from transplantation
baseline immunosuppression
Cyclosporin (8: 300)
steroids
Outcomes mortality
graft loss
acute rejection
infection/CMV
delayed graft function
malignancy
Notes 3 year follow-up
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
van Riemsdijk 2002
Methods Multicentre (Netherlands)
Participants N=130 (64 vs 66)
donor source and recipient status ns
Interventions 1. Daclizumab, 2 days steroids
2. normal steroids
Tacrolimus (ns: ns)
MMF (ns)
Outcomes acute rejection
Notes 6 months follow-up
Data from abstracts only
Risk of bias
Item Authors’ judgement Description
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van Riemsdijk 2002 (Continued)
Allocation concealment? Unclear B - Unclear
Dosage of IL2Ra, unless otherwise stated: basiliximab 20mg IV, day 0 and day 4 post transplantation; daclizumab 1mg/kg IV, 5 doses
at 2 weekly intervals from time of transplantation.
Baseline immunosuppression doses are given as: tacrolimus and cyclosporin (initial target dose mg/kg/d: trough target at 3 months ng/
ml); azathioprine ( initial dose mg/kg/d); mycophenolate mofetil (initial dose g/d); where dosage not stated ’ns’ recorded.
Unless otherwise stated in notes, no significant differences in demographic characteristics are reported for any comparative group.
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D A T A A N D A N A L Y S E S
Comparison 1. IL2Ra versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 3 months 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
1.2 6 months 6 977 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.38, 1.84]
1.3 1 year 13 2339 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.43, 1.40]
1.4 3 years 4 695 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.30, 1.29]
2 Graft loss or death with
functioning allograft
16 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 3 months 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
2.2 6 months 7 1081 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.52, 1.15]
2.3 1 year 14 2410 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.66, 1.04]
2.4 3 years 4 695 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.64, 1.22]
3 Acute rejection - biopsy proven 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 3 months 1 76 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.12, 1.45]
3.2 6 months 10 2223 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.56, 0.73]
3.3 1 year 7 1820 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.59, 0.76]
3.4 3 years 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
4 Acute rejection - clinical or
biopsy proven
17 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 3 months 3 163 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.25, 1.16]
4.2 6 months 12 2407 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.59, 0.74]
4.3 1 year 10 2052 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.60, 0.75]
5 Acute rejection - steroid resistant 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 3 months 1 55 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.01, 2.74]
5.2 6 months 7 1543 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.38, 0.67]
5.3 1 year 3 467 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.46, 0.84]
6 Malignancy - total 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 6 months 4 1040 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.09, 2.17]
6.2 1 year 9 1861 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.33, 1.36]
6.3 3 years 3 635 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.45, 1.53]
7 Infection - CMV all 12 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 3 months 1 55 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.01, 2.74]
7.2 6 months 7 1208 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.71, 1.20]
7.3 1 year 7 1528 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.65, 1.03]
8 Infection - CMV viraemia 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 3 months 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
8.2 6 months 3 613 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.57, 1.25]
8.3 1 year 4 952 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.40, 1.83]
8.4 3 years 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
9 Infection - CMV invasive 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 3 months 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
9.2 6 months 3 613 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.38, 2.78]
9.3 1 year 4 952 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.60, 1.42]
9.4 3 years 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
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10 Malignancy - non-melanotic
skin
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 6 months 1 302 Risk Ratio (M-H, Random, 95% CI) Not estimable
10.2 1 year 5 1002 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.13, 2.52]
10.3 3 years 2 535 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.32, 1.60]
11 Malignancy - other 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 6 months 1 302 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.06, 15.84]
11.2 1 year 7 1638 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.38, 1.93]
11.3 3 years 2 535 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.39, 2.73]
12 Delayed graft function 9 1380 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
13 Infection - total 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 3 months 1 60 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.86, 1.69]
13.2 6 months 5 848 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.79, 1.06]
13.3 1 year 3 822 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.92, 1.06]
14 Bacterial infection 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 3 months 1 60 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.90, 2.26]
14.2 6 months 2 420 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.73, 1.14]
14.3 1 year 3 822 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.74, 1.21]
15 Viral infection 8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 3 months 1 60 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.10, 2.53]
15.2 6 months 4 953 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.78, 1.18]
15.3 1 year 3 822 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.50, 1.13]
16 Fungal infection 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 3 months 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 15.26]
16.2 6 months 4 953 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.64, 1.25]
16.3 1 year 3 822 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.87, 1.62]
17 Graft loss censored for death
with functioning graft
16 Risk Ratio (M-H, Random, 95% CI) Subtotals only
17.1 3 months 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
17.2 6 months 6 977 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.49, 1.27]
17.3 1 year 14 2410 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.64, 1.10]
17.4 3 years 4 695 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.71, 1.59]
Comparison 2. IL2Ra versus other antibody
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 3 months 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
1.2 6 months 6 493 Risk Ratio (M-H, Random, 95% CI) 2.09 [0.68, 6.42]
1.3 1 year 7 593 Risk Ratio (M-H, Random, 95% CI) 1.96 [0.79, 4.90]
1.4 3 years 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
2 Graft loss or death with a
functioning graft
13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 3 months 1 40 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.01, 3.92]
2.2 6 months 8 625 Risk Ratio (M-H, Random, 95% CI) 1.52 [0.80, 2.88]
2.3 1 year 8 618 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.59, 2.25]
2.4 3 years 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
3 Acute rejection - biopsy proven 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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3.1 3 months 3 195 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.73, 1.76]
3.2 6 months 5 564 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.86, 1.99]
3.3 1 year 2 175 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.61, 1.53]
3.4 3 years 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
4 Acute rejection - clinical
suspicion or biopsy proven
15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 3 months 6 360 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.74, 1.51]
4.2 6 months 9 778 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.71, 1.39]
4.3 1 year 5 449 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.68, 1.24]
4.4 3 years 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
5 Acute rejection - steroid resistant 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 3 months 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
5.2 6 months 3 263 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.55, 2.20]
5.3 1 year 3 299 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.56, 2.10]
5.4 3 years 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
6 Malignancy - total 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.04, 3.15]
6.2 1 year 1 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.03, 2.90]
6.3 3 years 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
7 Infection - CMV all 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 3 months 3 203 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.29, 1.31]
7.2 6 months 4 494 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.22, 1.52]
7.3 1 year 3 299 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.30, 1.56]
7.4 3 years 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
8 Infection - CMV viraemia 3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8.1 3 months 1 Risk Ratio (M-H, Random, 95% CI) 1.6 [0.56, 4.56]
8.2 6 months 1 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.11, 0.65]
8.3 1 year 1 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.31, 2.11]
8.4 3 years 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
9 Infection - CMV invasive 3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
9.1 3 months 1 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.02, 1.65]
9.2 6 months 1 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.13, 71.92]
9.3 1 year 1 Risk Ratio (M-H, Random, 95% CI) 1.86 [0.48, 7.12]
9.4 3 years 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
10 Malignancy - non-melanotic
skin
2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
10.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.09]
10.2 1 year 1 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.04, 5.00]
10.3 3 years 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
11 Malignancy - other 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
11.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.05, 5.43]
11.2 1 year 1 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.01, 7.47]
11.3 3 years 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
12 Delayed graft function 8 645 Risk Ratio (M-H, Random, 95% CI) 1.37 [1.02, 1.84]
13 Chronic allograft nephropathy 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
13.1 1 year 1 Risk Ratio (M-H, Random, 95% CI) 1.5 [0.28, 8.04]
14 Infection - total 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 3 months 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.4 [0.53, 3.68]
14.2 6 months 2 312 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.77, 1.08]
14.3 1 year 1 135 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.82, 1.19]
15 All viral infections 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
15.1 3 months 1 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.13, 69.52]
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16 All bacterial infections 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
16.1 3 months 1 Risk Ratio (M-H, Random, 95% CI) 1.2 [0.44, 3.30]
17 Adverse reaction to study drug 4 475 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.17, 0.86]
18 Graft loss censored for death
with functioning graft
14 Risk Ratio (M-H, Random, 95% CI) Subtotals only
18.1 3 months 1 40 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.01, 3.92]
18.2 6 months 7 521 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.54, 2.56]
18.3 1 year 9 620 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.45, 2.10]
18.4 3 years 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
19 Acute rejection - clinical, by
antibody
9 778 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.71, 1.39]
19.1 ALG 1 25 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.08, 1.21]
19.2 ATG 6 680 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.73, 1.58]
19.3 OKT3 2 73 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.47, 2.21]
20 Leucopaenia 5 532 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.10, 0.46]
21 Thrombocytopaenia 4 431 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.16, 0.41]
22 Fever 4 281 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.17, 1.00]
23 Heterogeneity investigation
CMV Infection
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
23.1 CMV infection at 6
months
4 494 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.22, 1.52]
23.2 no Brennan CMV
infection at 6 months
3 217 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.22, 0.62]
24 Heterogenity investigation
adverse reaction to study drug
3 263 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.18, 0.47]
Comparison 3. Non-standard dose IL2Ra versus standard dose IL2Ra
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 1 year 1 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.36, 2.26]
2 Graft loss 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 1 year 1 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.51, 2.03]
3 Acute rejection - biopsy proven 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.48, 1.56]
3.2 1 year 1 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.48, 1.46]
4 Acute rejection - clinical
suspicion and biopsy proven
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.48, 1.56]
4.2 1 year 1 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.49, 1.37]
5 Delayed graft function 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Malignancy - total 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 1 year 1 Risk Ratio (M-H, Random, 95% CI) 3.06 [0.13, 74.22]
7 Infection - CMV total 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
7.1 1 year 1 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.34, 1.98]
8 Infection - total 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8.1 1 year 1 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.84, 1.15]
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Comparison 4. Stratification of Il2Ra versus antibody by other antibody
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Biopsy proven acute rejection at
3 months
3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 OKT3 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
1.2 Thymoglobulin 1 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.21, 4.44]
1.3 ATG 1 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.63, 2.27]
1.4 ALG 1 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.58, 2.14]
2 Mortality at 1 year 5 365 Risk Ratio (M-H, Random, 95% CI) 1.66 [0.63, 4.35]
2.1 OKT3 1 50 Risk Ratio (M-H, Random, 95% CI) 2.77 [0.31, 24.85]
2.2 Thymoglobulin 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
2.3 ATG 3 275 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.43, 4.18]
2.4 ALG 1 40 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.13, 69.52]
3 Graft loss at 1 year 5 365 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.50, 1.62]
3.1 OKT3 1 50 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.13, 1.64]
3.2 Thymoglobulin 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
3.3 ATG 3 275 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.51, 2.06]
3.4 ALG 1 40 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.20, 20.33]
4 Biopsy proven acute rejection at
6 months
4 475 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.87, 2.19]
4.1 OKT3 1 28 Risk Ratio (M-H, Random, 95% CI) 1.2 [0.47, 3.03]
4.2 Thymoglobulin 2 312 Risk Ratio (M-H, Random, 95% CI) 1.87 [0.81, 4.31]
4.3 ATG 1 135 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.50, 2.04]
4.4 ALG 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
5 Total CMV infection at 3
months
3 203 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.29, 1.31]
5.1 OKT3 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
5.2 Thymoglobulin 1 63 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.18, 0.94]
5.3 ATG 2 140 Risk Ratio (M-H, Random, 95% CI) 0.9 [0.40, 2.02]
5.4 ALG 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
Comparison 5. Basiliximab versus Daclizumab
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) Not estimable
2 Graft loss 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) Not estimable
3 Acute rejection - biopsy proven 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 3 months 1 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.02, 1.35]
3.2 6 months 1 Risk Ratio (M-H, Random, 95% CI) Not estimable
4 Acute rejection - steroid resistant 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) 1.3 [0.09, 18.33]
5 Malignancy - total 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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5.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) Not estimable
6 Infection - CMV total 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) 8.91 [0.51, 154.95]
Comparison 6. Indirect comparison of IL2Ra: basiliximab versus daclizumab
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Acute rejection - biopsy proven 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Basiliximab - 6 months 7 1590 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.56, 0.77]
1.2 Daclizumab - 6 months 3 633 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.47, 0.76]
1.3 Basiliximab - 1 year 5 1285 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.60, 0.80]
1.4 Daclizumab - 1 year 2 535 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.51, 0.81]
2 Acute rejection - clinical or
biopsy proven
13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Basliximab - 6 months 8 1694 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.59, 0.77]
2.2 Daclizumab - 6 months 3 633 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.53, 0.82]
2.3 Basiliximab - 1 year 6 1441 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.59, 0.77]
2.4 Daclizumab - 1 year 2 535 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.51, 0.81]
3 Malignancy - total 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Basiliximab - 6 months 3 765 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.10, 5.76]
3.2 Daclizumab - 6 months 1 275 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.01, 2.60]
3.3 Basiliximab - 1 year 6 1441 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.24, 1.15]
3.4 Daclizumab - 1 year 2 360 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.16, 7.35]
3.5 Basiliximab - 3 years 1 100 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.06, 15.55]
3.6 Daclizumab - 3 years 2 535 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.39, 1.72]
4 Infection - CMV all 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 6 months 7 1208 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.71, 1.20]
4.2 1 year 7 1528 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.65, 1.03]
5 Graft loss censored for death 16 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 6 months 6 977 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.49, 1.27]
5.2 1 year 14 2410 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.64, 1.10]
5.3 3 years 4 695 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.71, 1.64]
Comparison 7. IL2Ra + MMF with no calcineurin inhibitor versus calcineurin inhibitor + AZA with no IL2Ra
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) 2.67 [0.11, 62.42]
2 Graft loss 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) 1.77 [0.17, 18.26]
3 Acute rejection - biopsy proven 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 6 months 1 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.54, 3.72]
4 Infection - total 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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